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ABSTRACT 25 
2 
 
Chronic inflammation of the airways is a central component in lung diseases and is frequently 26 
associated with bacterial infections. Monitoring the pro-inflammatory capability of bacterial 27 
virulence factors in vivo is challenging and usually requires invasive methods. We have evaluated 28 
the benefit of using  a mouse model, transiently expressing the luciferase reporter gene under the 29 
control of an heterologous IL-8 bovine promoter, to detect and monitoring  lung inflammation. This 30 
experimental animal model is based on the transient transduction of the IL-8 promoter, a gene 31 
representing a major player during inflammation, essential for leukocytes recruitment to the 32 
inflamed tissue and potentially an appropriate molecular read-out for monitoring the activation of 33 
inflammatory pathways caused by bacterial virulence factors. Lung inflammation in mice was 34 
induced using the culture supernatants from  two Pseudomonas aeruginosa clinical strains, VR1 35 
and VR2,  isolated from patients affected by cystic fibrosis and showing  different phenotypes in 36 
terms of motility, colony characteristics and biofilm production as well as pyoverdine, pyocyanine 37 
release. More interesting, the strains differ also for the presence in supernatants of metalloproteases, 38 
a family of  virulence factors with known pro-inflammatory activity. In vivo imaging indicated that 39 
VR1 strain, releasing in its culture supernatant  metalloproteases and other virulence factors, 40 
induced lung inflammation while the VR2  strain presented with a severely reduced pro-41 
inflammatory activity. The bioluminiscence signal was clearly visible from 4 to 48 hours after 42 
supernatant instillation. The animal model was also used to test the anti-inflammatory activity of 43 
azithromycin, an antibiotic with demonstrated inhibitory effect on the synthesis of bacterial 44 
exoproducts. The inflammation signal in mice was in fact significantly reduced when bacteria grew 45 
in the presence of a sub-lethal dose of azithromycin causing inhibition of the synthesis of 46 
metalloproteases and other bacterial elements. The in vivo data were further supported by 47 
quantification of immune cells and cytokine expression in mouse broncho-alveolar lavage samples. 48 
The data presented indicate that the model is suitable to functionally monitor in real time the lung 49 
inflammatory response facilitating the identification of bacterial factors with pro-inflammatory 50 
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activity and the evaluation of the anti-inflammatory activity of  old and new molecules for 51 
therapeutic use.  52 
53 
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INTRODUCTION 54 
Airway inflammation is a central component of a number of chronic lung diseases such as severe 55 
asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and  bronchiectasis. 56 
Airway inflammation is characterized by edema, cellular infiltration, activated T lymphocytes and 57 
mast cells, increased airway secretions, and deposition of excess collagen [1, 2]. Frequently, the 58 
inflammation is associated with bacterial infections such as those caused by Pseudomonas  59 
aeruginosa, an opportunistic human pathogen involved in severe airway infections especially in 60 
patients suffering from CF and COPD [1, 3]. During the early onset of the lung infection, P. 61 
aeruginosa secretes a high number of virulence factors which are responsible for tissue damage and 62 
inflammation [4]. As the infection progresses, the bacterium switches off most of the virulence 63 
genes but synthesizes a biofilm matrix and becomes resistant to antibiotics causing a chronic 64 
disease frequently leading to respiratory failure and lung transplantation or death [4].  65 
Therefore, it is mandatory to identify those factors and conditions causing lung cell damage and 66 
favoring the passage from an acute to a chronic bacterial infection by monitoring, for long times, 67 
the inflammation process. Furthermore, to avoid the onset of the chronic phase of the infection, it is 68 
important to treat P. aeruginosa infection during the acute phase using efficient antibiotic therapy 69 
and anti-inflammatory drugs.  70 
By standard methods, the inflammation of the respiratory tract can be monitored by counting 71 
immunological markers recruited during the inflammatory process with sputum collection, a 72 
technique which provides poorly reliable results, or invasive sampling techniques such as 73 
bronchoscopy [5]. Animal models of acute and chronic lung infection have been used to  study the 74 
bacterial behavior and for monitoring the host response in vivo [1, 6]. These models provide an 75 
important resource to identify essential bacterial genes for in vivo infection persistence and for the 76 
development and testing of new therapies [6, 7]. Recently, a mouse model, transiently expressing 77 
the luciferase reporter gene under the control of the bovine IL-8 promoter, has been described [8] 78 
and demonstrated to be suitable to functionally monitor in real time the lung inflammatory response 79 
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[8, 9, 10,11].  This small size experimental animal model is based on the transient transduction of 80 
the IL-8 promoter, a gene representing a major player during inflammation, essential for leukocytes 81 
recruitment to the inflamed tissue and an appropriate molecular read-out for monitoring the 82 
activation of inflammatory pathways [8]. Although mice do not have an IL-8 gene, mouse cell 83 
signaling and their transcriptional apparatus could specifically activate the bovine IL-8 gene 84 
promoter. Since lung disease manifestation in ruminants overlap with the majority of human lung 85 
disease manifestations, this model could be of great value to study human lung diseases too.  86 
It has been shown that the P. aeruginosa strains isolated during the early phase of lung colonization 87 
had a pro-inflammatory capability higher than that induced by strains isolated during lung chronic 88 
colonization [12]. The pro-inflammatory effect, associated with the expression of IL-8 mRNA in 89 
CF airway epithelial cells, was shown to be associated to several Pseudomonas released proteins 90 
with proteolytic activity including members of the metalloprotease (MP) family [12]. Other 91 
virulence factors secreted by Pseudomonas such as  exotoxins and exoenzymes, pyoverdine and 92 
pyocianine are also involved in tissue damage and inflammation. It has been suggested that 93 
azithromycin (AZM), an antibiotic used in CF patients, could elicit  its anti-inflammatory activity 94 
by decreasing the synthesis of Pseudomonas exoproducts [13, 14, 15]. In fact, Molinari et al [13] 95 
have shown that sub-lethal doses of AZM strongly suppressed the synthesis of elastase, lecithinase, 96 
proteases and DNase, while in another study it has been shown that AZM reduced the production of 97 
bacteria virulence factors by inhibiting quorum-sensing [15].   98 
In the present study, the IL-8/luciferase transgenic mouse model has been used  in vivo to monitor 99 
the IL-8 mediated lung inflammation induced  by P. aeruginosa secreted pro-inflammatory 100 
virulence factors and their modulation by azithromycin.  101 
 102 
 103 
 104 
 105 
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MATERIALS AND METHODS 106 
 107 
Collection of bacterial cell-free supernatants  108 
Two P. aeruginosa strains, VR1 and VR2, were isolated from sputum samples of cystic fibrosis 109 
(CF) patients followed at the Cystic Fibrosis Center in Verona, Italy. Written informed consent was 110 
obtained from the subjects enrolled in the study and approved by the Institutional Review Board of 111 
Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona as project 1612.  112 
Bacterial strains were grown overnight at 37°C in BactoTM Tryptic Soy Broth (TSB, Becton, 113 
Dickinson and Company) with continuous agitation. The day after, P. aeruginosa cells were diluted 114 
in TSB to the concentration of 1x108 CFU/ml (OD of 0.1 at 600 nm) and incubated in absence and 115 
in presence of 8 µg/ml of AZM, at 37°C for 16 hours with continuous agitation. The concentration 116 
chosen for this antibiotic is in the sub-minimum inhibitory concentration (sub-MIC) range for P. 117 
aeruginosa, and is consistent with the concentrations found in lungs of patients treated with this 118 
drug (16). By adding TSB, the cultures were normalized to an optical density of 0.2 OD at 600 nm. 119 
Culture supernatants (Sn) were collected by centrifugation (7000 x g, 30 min, 4°C) and filtered 120 
through a 0.22 µm Millipore filter to remove any remaining bacteria. Supernatants were 121 
concentrated to 30X using Amicon Ultra-15 30K (Millipore, Billerica, USA), then centrifuged at 122 
27000 x g for 1 h at 4°C to remove cellular debris and finally sterilized by filtration through a 123 
Millipore 0.22 µm filter. 124 
 125 
Phenotype characterization  126 
 127 
Colony characterization: 128 
P. aeruginosa VR1 and VR2 isolates were grown on LB agar plates for 24-48 h at 37°C and colony 129 
morphotypes were visually inspected for color, shape, edges regularity, and mucoidy.  130 
 131 
7 
 
Motility assays: 132 
Swimming plates (1% tryptone, 0.5% NaCl and 0.3% (w/v) agar) were point-inoculated from 133 
an overnight culture with a sterile toothpick and incubated at 37 °C for 24 h. The zone diameter was 134 
measured to assess swimming motility. 135 
Swarming plates (0.5% peptone, 0.3% yeast extract, 0.5% NaCl, 0.5% D-glucose and 0.5% (w/v) 136 
agar) were point-inoculated from an overnight culture with a sterile toothpick and incubated at 37 137 
°C for 24 h. Swarming motility was assessed by measuring the circular turbid zones formed by the 138 
bacterial cells migrating away from the point of inoculation. 139 
Twiching motility was evaluated on Luria-Bertani (LB) 1% (w/v) agar plates. Overnight cultures 140 
were stabbed with a sterile toothpick through the agar layer to the bottom of the Petri dish. The 141 
plates were then incubated at 37 °C for 48 h. Twiching motility was examined by measuring the 142 
diameter of the halo formed in the plastic-agar interface. 143 
 144 
Biofilm formation assay 145 
Bacterial cells were grown at 37 °C in TSB-1% glucose until they reached the exponentially 146 
growing phase (OD650nm=0.4). Exponentially growing cells were then diluted in TSB-1% glucose 147 
medium to reach 106 CFU/ml. Two hundred microliter of each cell suspension were used to 148 
inoculate sterile flat-bottomed polystyrene microtiter plates (CytoOne, Starlab) and plates were 149 
incubated aerobically at 37 °C without agitation for 48 h to allow biofilm formation. After 150 
incubation, the planktonic cells were aseptically aspirated, washed with sterile physiological 151 
solution and dried. For biofilm quantification, 100 µl of 1% methylene blue were added to each 152 
well and the plate maintained for 15 minutes at room temperature. The wells were subsequently 153 
slowly washed once with sterile and dried at 37 °C. The methylene blue bound to the biofilm was 154 
extract using 100 µl of  70% ethanol and the absorbance measured at 570 nm using “A3 Plate 155 
Reader” microplate reader (DAS Srl, Italy). All the mentioned experiment were performed in 156 
triplicate. 157 
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Virulence factor assays 158 
The presence of  virulence factors in culture supernatants was evaluated after growth of the 159 
bacterial strains with and without azithromycin. 160 
Gelatin-zymography for analysis of the protease profile. 161 
Five ml of 5X SDS sample buffer (5% SDS, 0.5 M Tris-HCl pH 6.8, 25% glycerol) were added to 162 
20 µl of culture supernatants. The sample was run on a SDS-PAGE gel containing 1 mg/ml gelatin 163 
(Sigma-Aldrich) as described (12). The gel was washed twice (20 min per cycle) with 2.5% Triton 164 
X-100 at room temperature, then incubated in 200 ml of activation buffer (10 mM Tris-HCl, 1.25% 165 
Triton X-100, 5 mM CaCl2, 1 mM ZnCl2) overnight at 37 °C and finally stained with Coomassie 166 
Brilliant Blue G-250 in 20% methanol/10% phosphoric acid/10% ammonium sulfate and destained 167 
in water. 168 
In Vitro Imaging Probe  169 
A near infrared (NIR)-activatable “smart” probe (Perkin Elmer, Inc. Boston, MA, USA) was used 170 
for imaging protease activities. Specifically, MMPsense 750 FAST is a proteases activatable 171 
fluorescent in vivo imaging agent that is activated by key disease associated-proteinases such as 172 
MMPs including MMP-2, -3, -9 and -13 and bacterial proteases. Smart probes are optically silent in 173 
their inactivated state and becomes highly fluorescent following protease-mediated activation.  174 
The MMPsense 750 FAST probe was added to 50 µl of culture supernatants at the final 175 
concentration of 0.02 nmoles in a 96-well plate and an imaging system (IVIS, Caliper Life 176 
Sciences, Alameda, CA, USA) was used to quantify the time course of the fluorescence every 30 177 
sec from 1 to 40 min. 178 
Pyoverdine assay: 179 
The production of pyoverdine by P. aeruginosa was measured spectrophotometrically by a 180 
modification of the method described by Meyer and Abdallah. Overnight cultures of the strains 181 
were diluted to an optical density at 600 nm (OD600) of 0.1 in 30 ml of King's B broth (low-iron 182 
medium) with and without 8 µg/ml AZM and grown at 37°C until they reached an OD600 of ≈2-3 183 
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(after 16 h). Cultures were normalized to OD600 of 0.2 in order to reproduce the conditions of 184 
supernatants used for mice stimulation. The absorbance of cell-free supernatants was measured at 185 
405 nm. The concentration of pyoverdine was calculated by using the extinction coefficient (1.9 × 186 
10−4 M−1 cm−1). 187 
Pyocyanin assay: 188 
The pyocyanin assay is based on the absorbance of pyocyanin at 520 nm in acidic solution (Essar et 189 
al, 1990). Bacterial cultures were grown in LB medium with or without AZM following the same 190 
conditions described for pyoverdine assay. Five milliliters of cell-free supernatants were extracted 191 
with 3 ml of chloroform. The lower phase was mixed with 1 ml of 0.2 M HCl, and the absorbance 192 
of the resulting upper pink phase was measured at 520 nm (A520). Concentration, expressed as µg of 193 
pyocyanin per ml of culture supernatant, was determined by multiplying the A520 value by 17.072.  194 
 195 
Experimental Animals 196 
Female inbred BalbC (7–8 week-old) mice were purchased from Harlan Laboratories Italy (San 197 
Pietro al Natisone, Udine, Italy). Prior to use, animals were acclimatized for at least 5 days to the 198 
local vivarium conditions (room temperature: 20–24°C; relative humidity: 40–70%; 12-h light-dark 199 
cycle), having free access to standard rodent chow and softened tap water. Animal experiments 200 
were conducted in compliance with national (Decreto Legislativo numero 26, 4 Marzo 2014) and 201 
international laws and policies (Guide for the Care and Use of Laboratory Animals) [17]. Animal 202 
studies were approved by the Institutional Animal Care and Use Committee at Chiesi Farmaceutici, 203 
Parma, Italy.  204 
 205 
In Vivo Gene Delivery 206 
The bIL-8-Luc plasmid (Department of Medical Veterinary Science, University of Parma, Italy) 207 
was obtained by sub-cloning the 2030 bp IL8 bovine promoter, amplified by PCR from Madin-208 
Darby bovine kidney (MDBK; ATCC #CCL-22) genomic DNA and sub-cloned into the digested 209 
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pGL3basic vector (Promega) as previously described [8]. We applied in vivo JetPEI (Polyplus 210 
Transfection) as a carrier for delivering DNA to lung tissues. The DNA and JetPEI mix was 211 
formulated according to the product manual with a final N/P ratio of 7. Briefly, 40 µg of bIL-8–luc 212 
and 7 µL of JetPEI were both diluted into 200 µL 5% glucose. The two solutions were then mixed 213 
and incubated for 15 minutes at room temperature. The entire mixture was injected intravenously 214 
into BalbC mice and the expression of bIL-8–Luc was monitored through imaging with an IVIS 215 
imaging system. 216 
 217 
In Vivo Bioluminescence Imaging 218 
Transfection per se causes a mild lung inflammatory response and bIL-8 activation that is detectable 219 
by BLI up to 3–4 days after DNA injection and disappears completely after 1 week.  220 
One week after DNA delivery, the transient transgenic mice were injected intraperitoneally (i.p.) 221 
with luciferin (150 mg/kg) and bioluminescence imaging (BLI) was recorded in order to check the 222 
baseline activation of the IL-8 pathway.  Briefly, 10 and 15 min following luciferin injection, mice 223 
were lightly anesthetized with isoflurane and images were obtained using the IVIS imaging system: 224 
an average of photons emitted from the chest of the mice was quantified using Living Image® 225 
software (Caliper Life Sciences, Alameda, CA, USA).  Data were expressed as mean folds of 226 
induction (FOI) over  the baseline activation of each mouse. The following day, mice were 227 
intratracheally challenged with 10X supernatants and BLI was recorded at 4, 24, and 48 hours. 228 
 229 
Bronchoalveolar Lavage and Cytokine Determination 230 
Twenty-four hours after intratracheal challenge, animals were weighted, anaesthetized with 231 
isoflurane and sacrificed by bleeding from the abdominal aorta for bronchoalveolar lavage fluid 232 
(BALF) collection, performed as previously described [8]. BALF supernatants were frozen at -80 233 
°C for simultaneous quantitation of multiple cytokines/chemokines using a Bio-Plex™ Cytokine 234 
Assay Kit (Bio-Rad Laboratories, Segrate, Milano, Italy).  235 
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The cell pellet was suspended in 0.2 ml of PBS and total and differential cell counts were obtained 236 
using an automated cell counter (Dasit XT 1800J, Cornaredo; Milano, Italy). 237 
 238 
Reagents 239 
In vivo JetPEI DNA transfection reagent (Polyplus Transfection) was obtained from Euroclone 240 
(Milan, Italy), D-luciferin was obtained from Perkin Elmer Inc. (Boston, MA,USA). Azithromycin 241 
was from Pfizer (Italy). 242 
 243 
Data analysis 244 
Experimental values were expressed as the mean and standard error of the mean (SEM). Statistical 245 
analysis was performed using one-way analysis of variance followed by Dunnett’s t test (* p < 0.05, 246 
** p < 0.01). 247 
 248 
 249 
 250 
RESULTS 251 
Phenotypic characterization of Pseudomonas aeruginosa clinical isolates 252 
We  hypothesized that one or more virulence factors  released by P. aeruginosa in the lung of CF 253 
patients during infection might have a role as pro-inflammatory factors. Specifically and in addition 254 
to other released bacterial products, we considered tested the role of metalloproteases it has been 255 
demonstrated in CF airway epithelial cells that the pro-inflammatory role is mainly associated to 256 
Pseudomonas released proteins with proteolytic activity [12]. We have therefore selected two 257 
clinical P. aeruginosa strains, VR1 and VR2,   isolated from two different patients and showing 258 
significant differences as regards phenotypic characteristics and presence of metalloproteases and 259 
other virulence factors in culture supernatants. The phenotypic characterization of the two strains is 260 
shown in Table 1. VR1 and VR2  differentiated for the production of pyoverdin and pyocyanin 261 
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which are released only in the VR1 supernatant, the capability of moving by swimming, swarming 262 
and  twitching detectable in VR1 but non in VR2, the production of biofilm which is more evident 263 
in VR1 with respect to VR2 and by the level of protease activity, well detectable in the VR1 264 
supernatant and very reduced in the VR2 one.  265 
Culture supernatants were prepared from the two different  bacterial strains by grown them in a 266 
culture medium in the absence (SnVR1 and SnVR2) and in the presence of a sub-MIC dose of 267 
azithromycin (SnVR1+AZM and SnVR2+AZM). The inhibitory action of AZM on the expression 268 
of Pseudomonas virulence factors is clearly shown in Table 1. The specific inhibitory effect of 269 
AZM on metalloprotease synthesis was also demonstrated by testing supernatants for the presence 270 
of proteolytic activity with a proteases activable fluorescent probe (Figure 1) and by zymography 271 
(Figure 2) 272 
 273 
In vivo monitoring of lung inflammation induced by P. aeruginosa  culture supernatants on 274 
IL-8 transiently transgenic mice 275 
In vivo monitoring of lung inflammation after intra-tracheal challenge with P. aeruginosa SnVR1 276 
and SnVR2 at 1X, 3X, 10X and 30X concentrations was conducted by in vivo imaging in bIL-8 luc 277 
transient transgenic mice. Administration of the 10X SN concentration was sufficient to induce the 278 
maximal increase in BLI signal. In fact, the use of the 30X Sn preparation did not translate into a 279 
higher inflammation signal, indicating a saturation of the system at lower concentration (10X) 280 
(Figure 3A). For this reason, the rest of the experiments were conducted at 10X concentration.  281 
SnVR1 pro-inflammatory activity was clearly detectable as soon as 4 hours post instillation, 282 
although the BLI signal reached the highest peak at 24 hours (FOI 5.11±1.07) and was still 283 
detectable at 48 hours (Figure 3B). On the contrary, the SnVR2 did not induce detectable 284 
inflammation in the mouse lung at any time point.  The BLI signal induced by the challenge with 285 
SnVR1+AZI  was significantly low (FOI 1.58±0.21) after 24 hours with respect to the response 286 
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induced by SnVR1 obtained from the same bacterial strain grown without the antibiotic (Figure 287 
3B). 288 
 289 
Recruitment of inflammatory cells and cytokine activation induced by P. aeruginosa culture 290 
supernatants 291 
Twenty-four hours after mice stimulation with P. aeruginosa products, BALF was recovered from 292 
IL-8 transgenic animals treated with both VR1 and VR2 supernatants in order to compare their 293 
effect on cell recruitment and cytokine expression. SnVR1, containing a series of important 294 
virulence factors, significantly stimulated total white blood cells (WBC) and neutrophils 295 
recruitment (respectively 6.52x103±0.44 and 4.19x103±0.43cells/µl) and the expression of cytokines  296 
IL-1β, TNF-α, IL-17, RANTES, KC, IL 12 (p70) and IL 12 (p40) (Figures 4 and 5). SnVR2 profile 297 
differed from the one of  SnVR1, being the effect of SnVR2  lower with respect to both 298 
inflammatory cells recruitment (WBC 2.39±0.23x103 and neutrophils 1.70±.0.22 x103 cells/µl) and 299 
expression of the cited cytokines. SnVR2  showed a comparable effect on the release of RANTES 300 
and IL 12 (p40).  301 
BALF was recovered also from IL-8 transgenic mice stimulated with SnVR1+AZM and SnVR2 302 
+AZM in order to evaluate the effect of the antibiotic on the pro-inflammatory activity of both 303 
preparations. The challenge with SnVR1+AZM stimulated at a significant lower level WBC and 304 
neutrophils recruitment (respectively 4.07±0.39x103 and 2.05±03.4 x103 cells/µl) (Figure 4) and the 305 
expression of the cytokines IL-1β, IL-17, RANTES, KC and IL-12 (p70) but not that of TNF-α and 306 
IL 12 (p40) in comparison with animals treated with SnVR1 (figure 5). A significant difference 307 
between the stimulation caused by SnVR2 and SnVR2+AZM was not observed except for 308 
RANTES and IL12-(p40) level (Figure 5). 309 
 310 
 311 
 312 
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CONCLUSIONS 313 
The mechanisms and mediators that drive the induction and progression of chronic inflammation 314 
and altered lung function in a series of human diseases are not completely understood and this has 315 
severely hampered the development of effective treatments [1, 2, 3]. Although most of the animal 316 
models do not exactly mimic human lung diseases and each model has its own benefits and 317 
deficiencies, animal modelling systems that accurately reflect human disease pathophysiology 318 
continue to be essential for the development and validation of pathogenic aspects and new 319 
therapies. In most mammalian models, TNFα, IL-1β, and IL-8 are central components of a complex 320 
cytokine network that initiates, amplifies, and sustains the inflammatory response in tissue [18]. 321 
Available evidence also supports the importance of this network in coordinating acute inflammatory 322 
responses within the lung. The mouse model used in this study, transiently transgenized with a 323 
luciferase reporter gene under the control of the IL-8 bovine promoter, can be easily employed for 324 
monitoring the human lung inflammation due to the high similarity existing between respiratory 325 
diseases in ruminants and humans without the high costs and demands in terms of maintenance of 326 
ruminant models [8].  327 
In the present study, the IL8/luciferase mouse model has been applied to the in vivo monitoring of 328 
lung inflammation induced by virulence factors released by Pseudomonas aeruginosa and to the 329 
evaluation of the anti-inflammatory action of AZM as an inhibitor of the synthesis of bacterial 330 
factors involved in pathogenicity. Data here presented show that a P. aeruginosa clinical strain, 331 
isolated from early lung colonization in a CF patient, synthesized flagella and biofilm and produced 332 
and released pyocyanin and pyoverdine and proteins with metallo-protease activity. The synthesis 333 
and release of these virulence factors significantly decreased when bacteria were grown in the 334 
presence of AZM. The pro-inflammatory effect of strain VR1 has been shown in IL-8/luciferase 335 
transiently transgenic mice by applying in vivo imaging and further confirmed by the increase in 336 
WBC and neutrophils recruitment and cytokine levels in the airways of transgenized mice. On the 337 
contrary, the supernatant from bacteria grown in the presence of AZM, a condition associated with 338 
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a much lower production of virulence factors, stimulated the inflammatory response only at a very 339 
reduced level. Similar low levels of IL-8 promoter activation was observed when the supernatant of 340 
the P. aeruginosa VR2 strain lacking the specific virulence factors, was instilled in the airways of 341 
IL-8/luciferase transgenized mice.  342 
These data support the notion that  the clinical benefits associated to AZM treatment in CF patients 343 
might be at least in part due to the lowering of the exoproduct  synthesis induced by the antibiotic in 344 
bacterial cells.  345 
Data obtained in this study  demonstrate  that the model is suitable to functionally monitor in real 346 
time the lung inflammatory response to bacterial products with pro-inflammatory activity and to 347 
confirm and better understand the anti-inflammatory effect of azithromycin, an antibiotic frequently 348 
used in cystic fibrosis.  The non invasive nature of this mouse model and the possibility for bIL-8-349 
luc transiently transgenized mice to be stimulated with bacterial products for long times [8] enables 350 
the monitoring of a biological process longitudinally in the same mouse and represents an obvious 351 
advance for functional as well as pharmacological studies. The model might be adapted and applied 352 
to study the pathogenesis of lung inflammatory diseases such as cystic fibrosis, to identify 353 
bacterial/nonbacterial factors with pro-inflammatory activity and to predict the possible therapeutic 354 
effect of known and new molecules with a presumptive anti-inflammatory action.  355 
 356 
 357 
 358 
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Figure legends 419 
 420 
Figure 1. Protease activity of cell-free supernatants from Pseudomonas aeruginosa grown in the 421 
presence and the absence of azithromycin.   422 
 MMPsense 750 FAST was added to supernatants from VR1 and VR2 strains grown in presence or 423 
absence of AZM (SnVR1 ± AZM and SnVR2  ± AZM) concentrated 1X, 10X and 30X. IVIS 424 
imaging system has been used to quantify the time course of the fluorescence. Data were expressed 425 
as induction folds over baseline (bacterial growth medium TSB). Results are reported as mean ± 426 
SEM and significance attributed when P<0.05 (*) or P<0.01(**). 427 
 428 
Figure 2. Analysis of metalloproteases activity  in VR1 and VR2 bacterial lysates and culture 429 
supernatants.  MPs activity  in lysates (2A) and supernatants (2B)  from VR1 and VR2  430 
Pseudomonas aeruginosa strains grown with and without azithromycin, as shown by zymography 431 
assay.  432 
 433 
Figure 3.- In vivo imaging of lung inflammation induced by P. aeruginosa culture supernatants on 434 
IL-8 transiently transgenic mice 435 
A) Representative images of mice (n = 3 per group) transiently transgenized with bIL-8-Luc and 436 
intratracheally instilled with bacterial cell-free 1X, 3X, 10X and 30X supernatants from VR1. The 437 
growth medium TSB was used as a control. Mice were monitored at 4, 24 and 48 hours post 438 
stimulation by BLI drawing a region of interest (ROI) over the chest.  439 
19 
 
B) Representative images of mice (n = 8 per group) transiently transgenized with bIL-8-Luc and 440 
intratracheally instilled with bacterial cell-free, 10X supernatants from VR1 and VR2 strains grown 441 
in presence or absence of AZM (VR1 ± AZM and VR2  ± AZM). The growth medium TSB was 442 
used as a control. Mice were monitored at 4, 24 and 48 hours post stimulation by BLI drawing a 443 
region of interest (ROI) over the chest.  444 
Data are also presented as light intensity quantification of the ROI using the LivingImage software. 445 
The experiment was repeated 3 times and each point represents the mean ± standard error of 8 446 
animals. Data were expressed as folds of induction (FOI) over  baseline activity of each mice and 447 
statistical differences were tested by One Way ANOVA followed by Dunnet’s post hoc test for 448 
group comparisons. Results are reported as mean ± SEM and significance attributed when P<0.05 449 
(*) or P<0.01(**). 450 
 451 
Figure 4.- Immune cell recruitment during lung inflammation caused by P. aeruginosa 452 
supernatants.  Cellular infiltration into the lung of mice intratracheally instilled with bacterial cell-453 
free 10X supernatants from VR1 and VR2 strains grown in presence or absence of AZM (VR1 ± 454 
AZM  and VR2  ± AZM).  TSB is the  bacterial growth medium and was used as a control.  The 455 
amount of white blood cells and neutrophils found in BALF was expressed as number of cells per 456 
µl at 24 hours post treatment. The experiment was repeated 3 times and each point represents the 457 
mean ± standard error of 8 animals. Results are reported as mean ± SEM and significance attributed 458 
when P <0.05 (*) or P <0.01(**). 459 
 460 
Figure 5. Cytokines concentration in mice bronchial lavage fluid after stimulation with P. 461 
aeruginosa culture supernatants.  Cytokine levels in BALF of IL-8 transgenized mice 24 hours after 462 
intratracheally challenge with bacterial cell-free supernatants from VR1 and VR2 strains grown in 463 
presence or absence of AZM (VR1 ± AZM and VR2  ± AZM). Data were expressed as folds of 464 
induction (FOI) over the control (bacterial growth medium TSB) The experiment was repeated 3 465 
20 
 
times and each point represents the mean ± standard deviation of 8 animals. Results are reported as 466 
mean ± SEM and significance attributed when P <0.05 (*) or P <0.01(**). 467 
 468 
 469 
 470 
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Virulence factors and phenotypes P. aeruginosa strain   
VR1 
P. aeruginosa strain   
VR1 + AZM 
P. aeruginosa strain  
VR2 
P. aeruginosa strain  
VR2 + AZM 
Metallo-proteases  +++ + - - 
 
Pyocianin 
µg/ml 0,29 0,16 0,12 0,13 
Relative conc. 
(OD550/OD600) 
0,048 0,026 0,020 0,022 
Pyoverdine µg/ml 2,63 0,00 0,13 0,06 
Relative conc. 
(OD550/OD600) 
0,103 0,00 0,005 0,002 
 
 
Colony phenotype 
Colour Green Light brown Light brown Light brown 
Mucoidy No No Yes Yes 
Edges Jagged Jagged Regular Regular 
Morphology Swarming Swarming Round Round 
Biofilm production  +++ ND ++ ND 
Twiching ( cm) 0,8 0,7 0,6 0,8 
Swimming ( cm) 2,3 1,2 0,5 0,5 
Swarming ( cm) 1,6 1,2 0,3 0,4 
Figure 6
  
 
 
 
 
